Table 3. Experimental and model predicted percentage of injected dose per gram tumor tissue (% ID/g) using the fitted parameters.
| Tumor | Antibody Dose (μg) | Predicted (%ID/g) | Experiment al (%ID/g) | Predicted (pmol/g) | Experimental (pmol/g) | Experimental (% receptors) |
|---|---|---|---|---|---|---|
| 4T1 | 100 (−iRGD) | 2.64 | 2.50 | 17.6 | 16.6 | 10.3 |
| 100 (+iRGD) | 11.2 | 11.6 | 74.4 | 77.4 | 43.3 | |
| 60 (−iRGD) | 2.64 | 3.07 | 10.6 | 12.3 | 6.22 | |
| 60 (+iRGD) | 11.2 | 10.4 | 44.8 | 41.8 | 26.4 | |
| BT474 | 100 (−iRGD) | 4.15 | 3.94 | 28.6 | 27.1 | 1.53 |
| 100 (+iRGD) | 18.4 | 18.4 | 126 | 128 | 6.75 |
The amount of antibody in the tumor tissue after an injection of anti-mouse αv (4T1 tumor mice) or Trastuzumab (BT474 tumor mice) at different concentrations was determined experimentally after 1 h circulation as described the “Materials & Methods” section. The effect of iRGD on antibody uptake was evaluated. Data represent the mean %ID/g tissue (n = 3–5 mice per group).